# Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

> **NCT00259987** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Adenocarcinoma

## Interventions

- **DRUG:** Lapatinib (GW572016) oral tablets

## Key facts

- **NCT ID:** NCT00259987
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2009-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259987, "Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00259987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*